These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34873186)

  • 1. In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus.
    Jacob B; Makarewicz O; Hartung A; Brodt S; Roehner E; Matziolis G
    Sci Rep; 2021 Dec; 11(1):23425. PubMed ID: 34873186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure.
    Manasherob R; Mooney JA; Lowenberg DW; Bollyky PL; Amanatullah DF
    Clin Orthop Relat Res; 2021 Jul; 479(7):1471-1481. PubMed ID: 33835090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times.
    Di Pilato V; Ceccherini F; Sennati S; D'Agostino F; Arena F; D'Atanasio N; Di Giorgio FP; Tongiani S; Pallecchi L; Rossolini GM
    Diagn Microbiol Infect Dis; 2020 Feb; 96(2):114901. PubMed ID: 31761480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.
    Dunne MW; Sahm D; Puttagunta S
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():19. PubMed ID: 25885674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.
    Fernández J; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro.
    Jørgensen NP; Skovdal SM; Meyer RL; Dagnæs-Hansen F; Fuursted K; Petersen E
    Pathog Dis; 2016 Jun; 74(4):ftw019. PubMed ID: 27036412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can dalbavancin be used as a catheter lock solution?
    Díaz-Ruíz C; Alonso B; Cercenado E; Cruces R; Bouza E; Muñoz P; Guembe M
    J Med Microbiol; 2018 Jul; 67(7):936-944. PubMed ID: 29771236
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
    Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-biofilm activity of dalbavancin against methicillin-resistant
    Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halicin Is Effective Against Staphylococcus aureus Biofilms In Vitro.
    Higashihira S; Simpson SJ; Collier CD; Natoli RM; Kittaka M; Greenfield EM
    Clin Orthop Relat Res; 2022 Aug; 480(8):1476-1487. PubMed ID: 35583504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection.
    Chauvelot P; Dupieux-Chabert C; Abad L; Souche A; Ferry T; Josse J; Laurent F; Valour F;
    J Antimicrob Chemother; 2021 Oct; 76(11):2863-2866. PubMed ID: 34423360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).
    Knafl D; Tobudic S; Cheng SC; Bellamy DR; Thalhammer F
    Eur J Clin Microbiol Infect Dis; 2017 Apr; 36(4):677-680. PubMed ID: 27896496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
    Carper HT; Sullivan GW; Mandell GL
    J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.